Pharmacological and biochemical characterization of bradykinin B2 receptors in the mouse colon: Influence of the TNBS-induced colitis

Regulatory Peptides

Volumn 141, Issue 1-3, 2007, Pages 25-34

  Hara, Daniela Balz ^a   Fernandes, Elizabeth Soares ^a   Campos, Maria Martha ^b   Calixto, João B ^a  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^b PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Contractile mechanisms; Gastrointestinal tract; Pro inflammatory peptides; Receptor densities

Indexed keywords

3 (6 ACETAMIDO 3 PYRIDYL) N [N [2,4 DICHLORO 3 [(2 METHYL 8 QUINOLINYL)OXYMETHYL]PHENYL] N METHYLAMINOCARBONYLMETHYL]ACRYLAMIDE; ACETYLCHOLINE; BRADYKININ B2 RECEPTOR; CALCIUM CHANNEL L TYPE; CALCIUM CHANNEL N TYPE; ICATIBANT; LEUKOTRIENE; NEUROPEPTIDE; PROSTANOID; TRINITROBENZENESULFONIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; COLITIS; COLON; CONTROLLED STUDY; DRUG ANTAGONISM; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; UPREGULATION;

ACETYLCHOLINE; ANIMALS; BRADYKININ; CALCIUM CHANNELS, L-TYPE; CALCIUM CHANNELS, N-TYPE; COLITIS; COLON; DOSE-RESPONSE RELATIONSHIP, DRUG; KALLIDIN; LEUKOTRIENES; MALE; MICE; MUSCLE CONTRACTION; NEUROPEPTIDES; PROSTAGLANDINS; QUINOLINES; RECEPTOR, BRADYKININ B2; TRINITROBENZENESULFONIC ACID;

MUS;

EID: 33947594914     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.regpep.2006.12.013     Document Type: Article

References (49)

1. Regoli D., and Barabé J. Pharmacology of bradykinin and related kinins. Pharmacol Rev 32 (1980) 1-45
2. Farmer S.G., and Burch R.M. Biochemical and molecular pharmacology of kinin receptors. Annu Rev Pharmacol Toxicol 32 (1992) 511-532
3. Calixto J.B., Cabrini D.A., Ferreira J., and Campos M.M. Kinins in pain and inflammation. Pain 87 (2000) 1-5
4. Calixto J.B., Cabrini D.A., Ferreira J., and Campos M.M. Inflammatory pain: kinins and antagonist. Curr Opin Anaesth 14 5 (2001) 519-526
5. Marceau F., and Bachvarov D.R. Kinin receptors. Clin Rev Allergy Immunol 16 (1998) 385-401
6. 1 receptors: key G-protein-coupled receptors and their role in inflammatory and painful processes. Br J Pharmacol 143 (2004) 803-818
7. Clements J.A. The glandular kallikrein family of enzymes: tissue-specific expression and hormonal regulation. Endocr Rev 10 (1989) 393-419
8. Schachter M., Peret M.W., Billing A.G., and Wheeler G.D. Immunolocalization of the protease kallikrein in the colon. J Histochem Cytochem 31 (1983) 1255-1260
9. Schachter M., Longridge D.J., Wheeler G.D., Mehta J.G., and Uchida Y. Immunocytochemical and enzyme histochemical localization of kallikrein-like enzymes in colon, intestine, and stomach of rat and cat. J Histochem Cytochem 34 (1986) 927-934
10. Chen L., Richards G.P., Chao L., and Chao J. Molecular cloning, purification and in situ localization of human colon kallikrein. Biochem J 307 (1995) 481-486
11. Devani M., Cugno M., Vecchi M., Ferrero S., Di Bernardino F., Avesani E.C., de Franchis R., and Colman R.W. Kallikrein-kinin system activation in Crohn's disease: differences in intestinal and systemic markers. Am J Gastroenterol 97 (2002) 2026-2032
12. Isordia-Salas I., Pixley R.A., Li F., Sainz I., Sartor R.B., Adam A., and Colman R.W. Chronic intestinal inflammation and angiogenesis in genetically susceptible rats is modulated by kininogen deficiency. Int Immunopharmacol 2 (2002) 1895-1905
13. Stadnicki A., Mazurek U., Plewka D., and Wilczok T. Intestinal tissue kallikrein-kallistatin profile in inflammatory bowel disease. Int Immunopharmacol 3 (2003) 939-944
14. 2R receptors in human inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol 289 (2005) 361-366
15. Zelawski W., Machnik G., Nowaczyk G., Plewka D., Lorenc Z., Sosada K., and Stadnicki A. Expression and localisation of kinin receptors in colorectal polyps. Int Immunopharmacol 6 6 (2006) 997-1002
16. Cuthbert A.W., and Margolius H.S. Kinins stimulate net chloride secretion by the rat colon. Br J Pharmacol 75 (1982) 587-598
17. Bhoola K.D., Figueroa C.D., and Worthy K. Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol Rev 44 (1992) 1-80
18. 2 receptor antagonist, on the development of experimental ulcerative colitis in mice. Dig Dis Sci 44 (1999) 845-851
19. 2 receptor antagonist-treated rats. Jpn J Pharmacol 90 (2002) 59-66
20. Van Rossum J.M. Cumulative dose-response curves. Arch Int Pharmacodyn 143 (1963) 299-330
21. 2 receptors. J Pharmacol Exp Ther 268 (1994) 902-909
22. 2 kinin receptors in the bovine isolated coronary artery. Br J Pharmacol 116 (1995) 2473-2481
23. El Sayah M., and Calixto J.B. Study of the mechanisms involved in the bradykinin-induced contraction of the pig iris sphincter muscle in vitro. Eur J Pharmacol 458 (2003) 175-181
24. Geppetti P., Patacchini R., Cecconi R., Tramontana M., Meini S., Romani A., Nardi M., and Maggi C.A. Effects of capsaicin, tachykinins, calcitonin gene-related peptide and bradykinin in the pig iris sphincter muscle. Naunyn-Schmiedeberg's Arch Pharmacol 341 (1990) 301-307
25. Belvisi M.G., Miura M., Stretton D., and Barnes P.J. Capsazepine as a selective antagonist of capsaicin-induced activation of C-fibres in guinea-pig bronchi. Eur J Pharmacol 215 (1992) 341-344
26. Megens A.A., Ashton D., Vermeire J.C., Vermote P.C., Hens K.A., Hillen L.C., Fransen J.F., Mahieu M., Heylen L., Leysen J.E., Jurzak M.R., and Janssens F. Pharmacological profile of (2R-trans)-4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-piperidinyl]-N-(2,6-imethylphenyl)-1-acetamide (S)-Hydroxybutanedioate (R116301), an orally and centrally active neurokinin-1 receptor antagonist. J Pharmacol Exp Ther 302 (2002) 696-709
27. El Sayah M., and Calixto J.B. New evidence on the mechanisms underlying bradykinin-mediated contraction of the pig iris sphincter in vitro. Peptides 24 (2003) 1045-1051
28. Andrade E.L., Ferreira J., André E., and Calixto J.B. Contractile mechanisms coupled to TRPA1 receptor activation in rat urinary bladder. Biochem Pharmacol 72 1 (2006) 104-114
29. Wallace J.L., MacNaughton W.K., Morris G.P., and Beck P.L. Inhibition of leukotriene synthesis markedly accelerates healing in rat model of inflammatory bowel disease. Gastroenterology 96 1 (1989) 29-36
30. McCafferty D., Miampamba M., Sihota E., Sharkey K.A., and Kubes P. Role of inducible nitric oxide sintase in trinitrobenzene sulphonic acid induced colitis in mice. Gut 45 (1999) 864-873
31. 125I]-bradykinin binding sites in rat intestinal epithelia. Br J Pharmacol 87 (1986) 201-209
32. 2 receptor gene transcription in cultured guinea-pig tracheal smooth muscle cells. Naunyn-Schmiedeberg's Arch Pharmacol 359 (1999) 153-159
33. Bradford M.M. A rapid and sensitive method for quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 74 (1976) 3805-3809
34. Cloutier F., Ongali B., Campos M.M., Thibault G., Neugebauer W., and Couture R. Correlation between brain bradykinin receptor binding sites and cardiovascular function in young and adult spontaneously hypertensive rats. Br J Pharmacol 142 (2004) 285-296
35. 1 receptor expression induced by tissue damage in the rat portal vein: a critical role for mitogen-activated protein kinase and nuclear factor-κB signaling pathways. Circ Res 94 (2004) 1375-1382
36. Medeiros Y., and Calixto J.B. Analysis of the mechanisms underlying the biphasic responses to bradykinin in circular muscle from guinea pig ileum. Eur J Pharmacol 241 (1993) 157-163
37. Cabrini D.A., Kyle D.J., and Calixto J.B. A pharmacological analysis of receptor subtypes and the mechanisms mediating the biphasic response induced by kinins in the rat stomach fundus in vitro. J Pharmacol Exp Ther 277 (1996) 299-307
38. Griesbacher T., and Lembeck F. Analysis of the antagonistc actions of HOE 140 and other novel bradykinin analogues on the guinea-pig ileum. Eur J Pharmacol 211 (1992) 393-398
39. 2 antagonist FR 173657 on kinin-induced smooth muscle contraction and relaxation, vasoconstriction and prostaglandin release. Br J Pharmacol 121 (1997) 469-476
40. Ryan U.S., Avdonin P.V., Posin E.Y., Popov E.G., Danilov S.M., and Tkachuk V.A. Influence of vasoactive agents on cytoplasmic free calcium in vascular endothelial cells. J Appl Physiol 65 (1988) 2221-2227
41. 2 receptor activation on intracellular calcium, cell proliferation, and extracellular collagen secretion in mesangial cells from normal and diabetic rats. Can J Physiol Pharmacol 73 (1995) 848-853
42. Tanaka H.K., Watanabe K., Tamaru N., and Yoshida M. Arachidonic-acid metabolites and glucocorticoid regulatory mechanism in cultured porcine tracheal smooth-muscle cells. Lung 173 (1995) 347-361
43. Schlemper V., Medeiros R., Ferreira J., Campos M.M., and Calixto J.B. Mechanisms underlying the relaxation response induced by bradykinin in the epithelium-intact trachea in vitro. Br J Pharmacol 145 (2005) 740-750
44. Holzer P. Implications of tachykinins and calcitonin gene-related peptide in inflammatory bowel disease. Digestion 59 (1998) 269-283
45. Yiangou Y., Facer P., Dyer N.H., Chan C.L., Knowles C., Williams N.S., and Anand P. Vanilloid receptor 1 immunoreactivity in inflamed human bowel. Lancet 357 (2001) 1338-1339
46. Fujino K., de la Fuentes S.G., Takami Y., Takahashi T., and Mantyh C.R. Attenuation of acid induced oesophagitis in VR-1 deficient mice. Gut 55 (2006) 34-40
47. Hicks G.A. TRP channels as therapeutic targets: hot property, or time to cool down?. Neurogastroenterol Motil 18 (2006) 590-594
48. Bouma G., and Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Immunol 3 (2003) 521-533
49. Danese S., and Fiocchi C. Etiopathogenesis of inflammatory bowel disease. World J Gastroenterol 12 30 (2006) 4807-4812